GENE ONLINE|News &
Opinion
Blog

2021-02-09| COVID-19

South Africa Defers AstraZeneca Vaccinations as Vaccine Only Provides Minimal Protection against COVID-19 Variant

by Daniel Ojeda
Share To

On February 7th, the South African government decided to put the AstraZeneca vaccinations on hold after the COVID-19 vaccine was only 22% effective at preventing mild-to-moderate infections caused by the South African variant. This could result in a big setback for the World Health Organization and COVAX, as they planned to distribute around 150 million doses of the vaccine to lower-income countries in the first quarter of the year.

COVID -19 infections have resulted in over 2.3 million deaths, and it has infected more than 106 million people in a little more than a year. Vaccines are one of the main tools developed to stop this pandemic. New vaccines are being approved every month. However, the emergence of new variants resistant to some of these vaccines is concerning.

 

Vaccines vs. New COVID Variants

Viruses change and mutate constantly. Every time they reproduce, and every time they spread from one person to the next, they acquire small changes to their proteins. The same is true for the SARS-CoV-2, the virus responsible for COVID-19. These changes can make the virus better at infecting people or, even worse, become resistant to vaccines that were designed for the original strain.

Several new variants of the virus have been detected worldwide. These include more contagious variants such as the ones in the UK, South Africa, and Brazil. In addition to being more contagious, it was reported that the South African variant is more resistant to current antibody therapies. Besides, vaccines from Moderna and Pfizer-BioNTech have also been less effective against the variant but still above the 50% threshold necessary for approval.

A new report by the South African government suggests that AstraZeneca’s vaccine lowers the chance to develop mild-to-moderate COVID-19 by only 22%. In contrast, this same vaccine had a 75% efficacy against the original strain. More studies are necessary to determine if the vaccine still provides protection against hospitalizations and severe COVID-19. However, the results led the South African government to pause the vaccine rollout until a new approach is determined.

 

Trouble for the COVAX Program

COVAX is a program co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and World Health Organization (WHO). The goal is to negotiate with companies to develop and manufacture vaccines, as well as guarantee their access to lower-income countries.

Most of the doses COVAX had secure were from AstraZeneca. In the first quarter of the year, there were expected to distribute 150 million doses of this vaccine, and an additional 200 million doses in the second quarter. If the AstraZeneca vaccine is less effective, it could affect the vaccine rollout. In a press statement, the WHO reiterated the importance of slowing the spread of the virus. “We must do everything possible to reduce the circulation of the virus, prevent infections and reduce the opportunities for the SARS-CoV-2 to evolve resulting in mutations that may reduce the efficacy of existing vaccines.”, it reported on its website.

Related Article: Lilly Teams up with GSK, Vir to Fight New COVID-19 Variants Using Antibody Combo

References

  1. https://www.reuters.com/article/uk-health-coronavirus-safrica-idUSKBN2A80J2
  2. https://coronavirus.jhu.edu/
  3. https://www.who.int/news/item/08-02-2021-covax-statement-on-new-variants-of-sars-cov-2
  4. https://www.who.int/news/item/22-01-2021-covax-announces-new-agreement-plans-for-first-deliveries
  5. https://www.reuters.com/article/uk-health-coronavirus-science/south-african-virus-variant-may-resist-antibody-drugs-pfizer-biontech-vaccine-seems-to-work-vs-uk-variant-idINKBN29P2P1
  6. https://www.nytimes.com/2021/01/25/health/coronavirus-moderna-vaccine-variant.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Arab Health Congress Confirms Partnership with Dubai Health Authority
2024-01-12
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top